Solventum Co. (NYSE:SOLV) Position Reduced by Wellington Management Group LLP

Wellington Management Group LLP reduced its position in Solventum Co. (NYSE:SOLV) by 68.0% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 6,933 shares of the company’s stock after selling 14,735 shares during the quarter. Wellington Management Group LLP’s holdings in Solventum were worth $483,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in SOLV. Deseret Mutual Benefit Administrators purchased a new position in Solventum during the 2nd quarter worth approximately $25,000. Hollencrest Capital Management purchased a new position in shares of Solventum during the second quarter valued at $25,000. Family Firm Inc. acquired a new position in Solventum during the second quarter valued at $26,000. Copeland Capital Management LLC acquired a new stake in Solventum during the 3rd quarter worth about $26,000. Finally, Eagle Bay Advisors LLC purchased a new position in Solventum during the 2nd quarter valued at about $27,000.

Solventum Stock Up 0.0 %

SOLV opened at $66.83 on Friday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The business has a 50 day moving average price of $70.90 and a 200 day moving average price of $63.50. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $96.05.

Wall Street Analyst Weigh In

SOLV has been the subject of a number of research analyst reports. Stifel Nicolaus initiated coverage on shares of Solventum in a research report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price target for the company. Wolfe Research began coverage on shares of Solventum in a research report on Thursday, September 26th. They issued a “peer perform” rating for the company. Morgan Stanley boosted their price target on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. BTIG Research started coverage on Solventum in a report on Thursday, September 5th. They set a “neutral” rating for the company. Finally, Piper Sandler boosted their target price on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $68.29.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.